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Abstract
Intrahepatic cholangiocarcinoma (ICC), a malignant 
tumor derived from the intrahepatic bile duct epi-
thelium, has a poor prognosis and is refractory to con-
ventional chemotherapy and radiation therapy. Thus, 
there is an urgent need to develop new effective ther-
apeutic strategies for this disease. We previously 
found that L1 cell adhesion molecule (L1CAM) plays an 
important role in tumor progression of ICC, and we gen-
erated a murine mAb, A10-A3 (IgG1), that binds to the 
Ig1 domain of L1CAM. In the present study, we further 
characterized A10-A3, constructed a chimeric A10-A3 
antibody (cA10-A3) containing the constant regions of 
human IgG1, and evaluated the therapeutic potential 
in a human ICC xenograft nude mice model. The affin-
ities (KD) of A10-A3 and cA10-A3 for soluble L1CAM 
were 1.8 nM and 1.9 nM, respectively, as determined by 
competition ELISA. A10-A3 inhibited L1CAM homo-
philic binding and was slowly internalized into the tu-
mor  cells,  but  it  did  not  significantly  inhibit  pro-
liferation of ICC cells in vitro. cA10-A3 mediated anti-
body-dependent  cell-mediated  cytotoxicity  in vitro 
and displayed anti-tumor activity in the ICC animal 
model. These results suggest that the humanized 
A10-A3 antibody may have potential as an anticancer 
agent for the treatment of ICC.
Keywords: immunization, passive; intrahepatic chol-
angiocarcinoma; neural cell adhesion molecule L1 
Introduction
Cholangiocarcinoma is a malignant tumor that arises 
from the bile duct epithelium. Cholangiocarcinoma 
is classified anatomically into intrahepatic chol-
angiocarcinoma (ICC) and extrahepatic chol-
angiocarcinoma (ECC) that have different risk fac-
tors, pathogeneses, and clinical features due to the 
distinct development and differentiation of intra-
hepatic and extrahepatic bile duct epithelium 
(Nakeeb et al., 1966; Shiojiri, 1997; Shaib et al., 
2007). ICC occurs at a higher incidence in 
Southeast Asia than in Europe and North America, 
but the incidence and mortality rates are increasing 
worldwide (Nakeeb et al., 1966; Patel, 2001; 
Taylor-Robinson  et al., 2001). Since chol-
angiocarcinoma is refractory to conventional che-
motherapy and radiation treatment (Sirica, 2005), 
complete surgical resection is currently the only 
treatment and cure. However, because of a lack of 
early diagnosis, most patients have occult meta-
stasis or advanced local disease on clinical pre-
sentation (Lazaridis and Gores, 2005). Moreover, 
prognosis of cholangiocarcinoma is very poor (Khan 294    Exp. Mol. Med. Vol. 44(4), 293-302, 2012
Figure 1. (A) Analysis of purified L1CAM proteins. Lane 1, purified hL1-ECD-Fc; Lane 2, hL1-ECD-S1; and Lane M, molecular weight standards. Proteins 
were subjected to 10% SDS-PAGE. Protein bands were visualized by Commassie blue staining. (B) Affinity determination of anti-L1CAM mAbs. 
Antigen-binding activities of A10-A3 (•) and cA10-A3 (▽) were determined by indirect ELISA. (C) Affinity determination of A10-A3. Antigen-binding affin-
ities of A10-A3 (•) and chimeric A10-A3 (▽) were determined by competition ELISA. Inset represents a Klotz plot.
et al., 2005). Thus, new effective therapeutic strat-
egies for this disease are urgently needed.
    The  L1  cell  adhesion  molecule  (L1CAM)  is  a 
member of the immunoglobulin (Ig) superfamily; it is 
a 200 to 220-kDa transmembrane glycoprotein 
consisting of six Ig-like domains followed by five 
fibronectin (Fn)-type III repeats, a transmembrane 
domain, and a short cytoplasmic tail (Moos et al., 
1988). L1CAM was first described as a neural cell 
adhesion molecule and has been shown to play key 
roles in the development of the nervous system, 
including cell adhesion, neurite outgrowth, axon 
guidance, neural cell migration, and myelination 
(Rathjen and Schachner, 1984; Brummendorf and 
Rathjen, 1995; Kaifi et al., 2006). L1CAM promotes 
cellular activities through L1 homophilic interaction, 
as well as heterophilic interaction with other 
neuronal members of the Ig superfamily, integrins, 
extracellular matrix proteins and cell surface 
receptors (reviewed in Haspel and Grumet, 2003). 
Recent reports have shown that L1CAM is 
aberrantly expressed in several different types of 
cancers, including colon carcinoma, ovarian and 
uterine carcinomas, malignant gliomas, recurrent 
neuroblastoma, cutaneous malignant melanoma, 
renal cell carcinoma, ECC and gallbladder 
carcinoma, and that its expression correlates with 
more advanced stages of tumor progression (Li et 
al., 2009; reviewed in Raveh et al., 2009; Choi et al., 
2011). In addition, ectopic L1CAM expression in 
carcinoma cells enhances their migration, invasion, 
and tumorigenesis (Silletti et al., 2004; Gast et al., 
2005; Gavert et al., 2005; Min et al., 2010). In 
addition to functioning as a cell surface adhesion 
molecule, the extracellular domain of L1CAM can be 
shed from the cell surface via proteolytic cleavage 
and can stimulate the migration and survival of 
tumor cells through autocrine/ paracrine binding to 
integrins (Duczmal et al., 1997; Mechtersheimer et 
al., 2001; Voura et al., 2001; Gutwein et al., 2003). A 
monoclonal antibody (mAb) against L1CAM reportedly 
inhibits the growth and dissemination of ovarian 
carcinomas in nude mice (Arlt et al., 2006; Wolterink 
et al., 2010).
    By immunizing mice with human ICC cell lines, 
we previously generated a murine mAb, A10-A3 
(IgG1, κ), that specifically binds to human L1CAM 
(Min et al., 2010). Immunohistochemical analysis of 
ICC tumor tissues using A10-A3 revealed L1CAM 
expression in 40.5% of the ICC patients. A functional 
study of L1CAM suppression or overexpression in 
ICC tumor cells indicated that L1CAM plays an 
important role in tumor progression of ICC by 
promoting cell proliferation, migration, and survival 
(Min  et al., 2010). These results suggested that 
L1CAM may serve as a therapeutic target in ICC 
and that anti-L1CAM mAb may have potential as 
diagnostic and therapeutic agents for the treatment 
of ICC. To characterize A10-A3, we performed 
epitope mapping, which showed that A10-A3 binds 
to the Ig1 domain of L1CAM (Wei et al., 2011). In the 
present study, we have further characterized 
A10-A3, constructed chimeric A10-A3 (cA10-A3), 
and evaluated its therapeutic potential in a human 
ICC xenograft nude mice model.
Results
Affinity determination of A10-A3
To determine the affinity of A10-A3 for L1CAM, 
hL1-ECD-S1 was produced and purified by affinity 
chromatography on anti-preS1 mAb KR127-coupled 
Sepharose columns (Maeng et al., 2000; Ryu et al., 
2000). After its purity and integrity was confirmed by Chimeric antibody to L1CAM    295
Figure 2. (A) Flow cytometric analy-
sis of ICC cells. Levels of L1CAM 
expression in ICC cells were ana-
lyzed by flow cytometry using A10- 
A3. Uncolored populations indicate 
A10-A3 staining; colored populations 
indicate control staining. (B) Confocal 
microscopic analysis of A10-A3 
internalization. SCK-L1 cells were 
preincubated with A10-A3 (20 μg/ml) 
for the indicated times. A10-A3 was 
detected using Alexa-488-conjugated 
goat anti-mouse IgG (green), and 
nucleus was counterstained with 
DAPI (blue). Merging of the two sig-
nals is shown at lower right panel for 
each time point.
SDS-PAGE (Figure 1A, lane 2), the purified 
hL1-ECD-S1 protein was used as an antigen to 
determine the affinity of A10-A3 by an indirect 
ELISA followed by a competition ELISA (Figures 1B 
and 1C). The affinity (KD) of A10-A3 for hL1-ECD-S1 
was 1.8 nM.
Internalization of A10-A3 into tumor cells
The anti-cancer therapeutic antibodies trastuzumab 
and cetuximab bind to Her2 and epidermal growth 
factor receptor (EGFR), respectively, and are in-
ternalized into target tumor cells where they down 
regulate receptor expression on the cell surface 
(Mendelsohn, 1997; Liang et al., 2003). To examine 
whether A10-A3 is internalized after binding to the 296    Exp. Mol. Med. Vol. 44(4), 293-302, 2012
Figure 3. (A) Analysis of purified L1CAM proteins. Lane 1, purified hL1-ECD-Fc; Lane 2, Ig1-Fc; Lane 3, Ig5-6/Fn1-5-Fc; and Lane M, molecular weight 
standards. Proteins were subjected to 10% SDS-PAGE. Protein bands were visualized by Commassie blue staining. (B) L1CAM homophilic binding as-
say; 2 μM hL1-ECD-S1 (hL1-S1) was incubated with purified hL1-ECD-Fc (hL1-Fc), Ig1-Fc, or BSA coated on each well. For the inhibition assay, 2 μM 
hL1-S1 was preincubated with A10-A3 (0, 1, 2, 5, 10, 20, or 50 μg) and allowed to bind to hL1-Fc captured by anti-Fc coated on the well. (C) Cell adhe-
sion assay. SCK-L1 cells were incubated with purified hL1-Fc, Ig1-Fc, Ig5-6/Fn1-5-Fc, or BSA. For the inhibition assay, SCK-L1 cells were preincubated 
with mock or 10 μg of A10-A3, UJ127, or KR127 and allowed to bind to hL1-Fc coated on the well. Assays were performed three independent times in 
duplicate.
cells, we incubated Choi-CK, SCK (Kim et al., 2008), 
or L1CAM-overexpressing SCK-L1 cells (Min et al., 
2010) with A10-A3 for indicated time periods. Then 
the cells were labeled with an Alexa-488-conjugated 
secondary antibody, and analyzed by confocal 
microscopy. In 1 h, A10-A3 effectively bound to the 
plasma membrane of the cells, and it was in-
ternalized into endocytic vesicles of the SCK-LI cells 
at 6 h after the antibody treatment (Figure 2B). 
However, internalization of A10-A3 was not detected 
in Choi-CK and SCK cells (data not shown), prob-
ably because these cells express lower levels of 
L1CAM compared to SCK-L1 cells (Figure 2A).
Inhibition of L1CAM homophilic binding by A10-A3
It was recently demonstrated that the four N-terminal 
Ig-like domains (Ig1-4) mediate L1CAM homophilic 
binding in trans with approximately 100 nM of KD 
and that this promotes neurite outgrowth from 
human neurons (Gouveia et al., 2008). Additionally, 
Ig6 was shown to be involved in heterophilic binding 
with integrins (Haspel and Grumet, 2003). Since 
A10-A3 binds to the Ig1 domain with a high affinity, it 
may efficiently block L1CAM homophilic binding. To 
test this, a cell-free homophilic binding assay was 
established using purified hL1-ECD-S1 and 
hL1-ECD-Fc that was captured by anti-Fc antibodies 
immobilized on the wells (Figure 1A). As shown in 
Figure 3B, hL1-ECD-S1 bound to hL1-ECD-Fc, but 
did not bind to purified Ig1-Fc (Figure 3A, lane 2) or 
BSA. Subsequently, hL1-ECD-S1 was pre-incubated 
with different concentrations of A10-A3 and allowed 
to bind to hL1-ECD-Fc. A10-A3 inhibited the 
homophilic binding in a dose-dependent manner 
(Figure 3B). 
    Next, a cell adhesion assay was performed by 
using SCK-L1 cells and hL1-ECD-Fc that was 
captured by anti-Fc antibodies immobilized on the 
wells. As shown in Figure 3B, SCK-L1 cells bound to 
hL1-ECD-Fc, but did not bind to Ig1-Fc or BSA. The 
cells also showed weak binding to purified 
Ig5-6/Fn1-5-Fc (Figure 3A, lane 3), which lacks 
Ig1-4 that mediate homophilic binding but contains 
Ig6 that can bind to integrins. The binding of Ig5-6/ 
Fn1-5-Fc to the cells was approximately 25% that of 
hL1-ECD-Fc, indicating that L1CAM homophilic 
binding mediated by Ig1-4 is much stronger than 
L1CAM-integrin binding. For the inhibition study, 
cells were preincubated with A10-A3 or control 
antibody for 3 h and allowed to bind to hL1-ECD-Fc. 
A10-A3 efficiently inhibited the binding between the 
cells and hL1-ECD-Fc, decreasing the binding to a 
level that was similar to the binding observed 
between the cells and Ig5-6/Fn1-5-Fc. On the other 
hand, the UJ127 antibody, which binds to the Fn 
domain of L1CAM (Arlt et al., 2006) or KR127 as an 
isotype control, did not inhibit the binding of the cells 
to hL1-ECD. The results suggest that A10-A3 
specifically inhibits L1CAM homophilic binding.
    Finally, a proliferation assay was performed using 
Choi-CK, SCK, and SCK-L1 cells, as described in 
the materials and methods. A10-A3 hardly inhibited 
the proliferation of the cells (data not shown).Chimeric antibody to L1CAM    297
Figure 4. ADCC activity of cA10-A3. (A) ADCC assay using SCK-L1 
(target cells) and PBMC (effector cells). The ratio of effector:target (E:T) 
was 30:1. (B) ADCC assay using 10 μg/ml cA10-A3 and a 30:1 or 60:1 
ratio of E:T.
Figure  5. Inhibition of ICC tumor growth in nude mice by cA10-A3 
treatment. (A) cA10-A3 antibody or the isotype control Synagis was intra-
venously injected at a dose of 10 mg/kg three times a week for 28 days 
in nude mice bearing Choi-CK xenograft. (B) Body weights of tu-
mor-bearing mice.
Construction and characterization of cA10-A3
Distinct subclasses of IgG display substantial 
differences in their ability to mediate effector functions 
(Nimmerjahn and Ravetch, 2005). The mouse IgG2a 
was most effective and much more efficient than the 
mouse IgG1 variant of the same mAb, while human 
IgG1 was most effective in ADCC and CDC 
(Nimmerjahn and Ravetch, 2006). With the aim of 
validating the therapeutic potential of A10-A3 in 
nude mice bearing ICC xenograft, we replaced 
mouse IgG1 with human IgG1 to construct cA10-A3. 
The resulting chimeric antibody was expressed in 
DHFR-deficient CHO cells. After selection in G418 
and adaptation in a medium containing 20 nM MTX, 
the transfected cells were cultured in a protein-free 
medium and the chimeric antibody secreted in the 
culture supernatant was purified by affinity 
chromatography on a Protein A column. The purified 
cA10-A3 was subjected to competition ELISA for 
affinity determination; the affinity (KD) of cA10-A3 
was 1.9 nM, similar to that of A10-A3 (Figures 1B 
and 1C).
ADCC activity of cA10-A3
To evaluate whether cA10-A3 mediates antibody- 
dependent cell-mediated cytotoxicity (ADCC), a 
standard lactate dehydrogenase (LDH) assay was 
performed using SCK-L1 as target cells and human 
PBMC as effector cells. The SCK-L1 cells were 
pre-incubated with serially diluted cA10-A3 (0-10 
μg/ml), then incubated with human peripheral blood 
mononuclear cells (PBMC) at a 30:1 ratio of 
effector:target (E:T) cells. The cA10-A3 was effective 
in inducing ADCC against SCK-L1 cells in a 
dose-dependent manner (Figure 4A), and the ADCC 
activity of antibody at 10 μg/ml concentration was 
increased with the ratio of E:T 60:1 (Figure 4B). 
However, the antibody did not induce ADCC against 
Choi-CK cells that express low level of L1CAM (data 
not shown). This may be because L1CAM expression 
in Choi-CK cells is too low to induce ADCC. 
Inhibition of ICC tumor growth in nude mice by 
cA10-A3
To evaluate the therapeutic efficacy in vivo, cA10-A3 
or the isotype control palivizumab (Synagis, a 
humanized antibody to respiratory syncytial virus F 
protein) was i.v. injected three times a week for 28 
days into nude mice bearing Choi-CK xenografts. 
The cA10-A3 inhibited the tumor growth in nude 
mice without affecting body weight (Figure 5). Since 
we observed that cA10-A3 did not induce ADCC 
against the Choi-CK cells in vitro, we examined 
whether the Choi-CK cells in the xenograft 
expressed a higher level of L1CAM compared to 
that of the cells cultured in vitro. Choi-CK cells were 
injected into nude mice and the tumor cells from the 
xenograft at day 7 post injection was prepared and 
subjected to flow cytometric analysis. The result 
showed that the level of L1CAM expression in the 
tumor cells from the Choi-CK xenograft was 
significantly higher than that in the Choi-CK cells 
cultured  in vitro (Supplemental Data Figure 1), 
suggesting that the increased L1CAM expression 
level in the Choi-CK cells may be sufficient to induce 
ADCC in nude mice.
Discussion
Cholangiocarcinoma is a malignant tumor with a 
poor prognosis and is refractory to conventional 
chemotherapy and radiation treatment. Thus, new 
effective therapeutic strategies for cholangiocarcinoma 
are urgently needed. L1CAM is aberrantly expressed 
in several types of tumors and plays important roles 
in tumor progression by enhancing cell proliferation, 298    Exp. Mol. Med. Vol. 44(4), 293-302, 2012
migration, and survival. Anti-L1CAM mAb has 
displayed therapeutic activity in a mouse model for 
ovarian carcinoma (Arlt et al., 2006; Wolterink et al., 
2010). Previously, we found that L1CAM is involved 
in tumor progression of ICC, ECC, and gallbladder 
carcinoma; we generated a murine mAb, A10-A3 
(IgG1) binding to the Ig1 domain of L1CAM (Li et al., 
2009; Min et al., 2010; Choi et al., 2011; Jung et al., 
2011; Wei et al., 2011). In the present study, we 
constructed the cA10-A3 containing the constant 
regions of human IgG1, confirmed its ADCC activity 
in vitro, and evaluated its therapeutic activity in a 
Choi-CK xenograft model. The cA10-A3 inhibited 
tumor growth in nude mice, suggesting potential for 
anti-L1CAM therapeutic antibodies as an anti-cancer 
agent for the ICC treatment.
    The results of the internalization assay indicated 
that A10-A3 was internalized into endocytic vesicles, 
suggesting that the L1CAM bound by A10-A3 may 
be also internalized. However, the endocytic vesicles 
were not detected until 3 h after addition of the 
antibody and were clearly detected at 6 h. This 
suggests that internalization of A10-A3 proceeds 
slowly in the cells and thus may not substantially 
impact the ADCC activity of A10-A3. In contrast, a 
previous study using human epidermoid carcinoma 
cells showed that anti-EGFR mAb, mAb-225 was 
internalized into endocytic vesicles within 1 h 
(Sunada et al., 1986). 
    L1CAM plays an important role in tumor pro-
gression through homophilic binding and heterophilic 
interaction with other cell surface proteins, such as 
growth factor receptors and integrins. For example, 
the Ig6 domain of L1CAM contains an RGD motif 
that interacts with αvβ3 integrin; inhibition of this 
binding significantly reduces haptotactic migration 
of melanoma cells (Montgomery et al., 1996). In ad-
dition, L1CAM interacts with fibroblast growth factor 
receptor to confer enhanced cell motility and in-
vasion of L1CAM-overexpressing ovarian cancer 
cells (Zecchini et al., 2008). However, it has not 
been clearly shown whether inhibition of L1CAM ho-
mophilic binding can influence tumor cell proliferation. 
In the present study, we observed that A10-A3 in-
hibited L1CAM homophilic binding, but did not sig-
nificantly inhibit ICC cell proliferation in vitro. This in-
dicates that blocking L1CAM homophilic binding is 
not sufficient to inhibit tumor cell proliferation, and 
suggests that L1CAM homophilic binding may play 
a minor role in proliferation of ICC cells. Considering 
this finding along with the fact that L1CAM over-
expression enhanced proliferation of ICC cells (Min 
et al., 2010), it seems likely that heterophilic inter-
action of L1CAM with integrins and/or growth factor 
receptors or other indirect mechanism may have 
promoted the cell proliferation. We found that EGFR, 
hepatocyte growth factor receptor, and integrins 
(αvβ3, αvβ5, and β1) are expressed on the surface 
of ICC cells (Yoon et al., 2012). It will be interesting 
to study the exact mechanism of heterophilic inter-
actions between L1CAM and these molecules, and 
how these interactions influence cellular functions in 
ICC cells. It might also be valuable to generate an-
ti-L1CAM antibodies that can inhibit these hetero-
philic interactions to evaluate their therapeutic po-
tential for the development of more effective anti-
cancer antibodies.
    Taken together, our results suggest that cA10-A3 
inhibits L1CAM homophilic binding and mediates 
ADCC, while it is internalized into the tumor cells 
slowly. The cA10-A3 displayed anti-tumor activity in 
a human ICC xenograft nude mice model. Therefore, 
a humanized A10-A3 antibody may be used as an 
anticancer agent for the treatment of ICC.
Methods
Cell culture
SCK and Choi-CK cell lines, established from tumor sam-
ples from Korean patients with ICC (Yoo et al., 2009), 
L1CAM-overexpressing SCK (SCK-L1) cells (Min et al., 
2010), and human embryonic kidney HEK293 cells were 
grown in DMEM (Invitrogen) with 10% fetal bovine serum 
(FBS; Hyclone) in 5% CO2, 37
oC humidified incubator. The 
dihydrofolate reductase (DHFR)-deficient Chinese hamster 
ovary (CHO) cell line, DG44 were grown in DMEM/F12 
(Invitrogen) supplemented with hypoxanthine (10 mg/L), 
thymidine (10 mg/L), glycine (50 mg/L), glutamine (587 
mg/L), glucose (4.5 mg/L), 10% fetal bovine serum, and 
Antibiotics-Antimycotics (Invitrogen).
Expression and production of the extracellular 
domains of human L1CAM
The cDNA (L1 cDNA) isolated from Choi-CK cells (Min et 
al., 2010) was used as template for PCR. The cDNA en-
coding the hL1-ECD (amino acids, aa 1-1082) was synthe-
sized by PCR from the L1 cDNA using pfu turbo polymer-
ase (Stratagene) and the primers (forward primer, 5'-ATG 
GTCGTGGCGCTGCGGTAC-3'; reverse primer, 5'-TGGAG 
ACTGTTCCGTGATGAC-3'). PCR reactions were per-
formed in a thermocycler (MJ research) with the following 
cycling parameters: denaturation at 94
oC for 5 min; then, 
25 repetitive cycles of 95
oC for 45 seconds, annealing at 
56
oC for 45 seconds, and elongation at 72
oC for 4 min. The 
final extension was performed at 72
oC for 7 min followed 
by rapid cooling at 4
oC. The resulting PCR product was 
cloned into pCR2.1-TOPO (Invitrogen) and sequenced by 
the DNA ABI 377 automated sequencer. Results were ana-
lyzed using the blast search tool in NCBI (http://www.ncbi. 
nlm.nih.gov/).
    For the expression of the hL1-ECD fused to the preS1 
tag (Oh et al., 2003) or the Fc of human immunoglobulin 
IgG1, the hL1-ECD cDNA was subcloned into the Chimeric antibody to L1CAM    299
EcoRI-XhoI sites of pJK-dhfr2 (Aprogen, Korea) containing 
the preS1 tag or pJK-dhfr2-Fc (Aprogen, Korea) to con-
struct pJK-dhfr2-hL1-ECD-S1 or pJK-dhfr2-hL1-ECD-Fc, 
respectively. For the expression of the Ig1 or Ig5-6/Fn1-5 
fused to the Fc, the cDNA encoding the Ig1 (aa 1-126) or 
Ig5-6/Fn1-5 (aa 396-1082) was synthesized by PCR and 
subcloned into pJK-dhfr2-Fc to construct pJK-dhfr2-Ig1-Fc 
or pJK-dhfr2-Ig5-6/Fn1-5-Fc, respectively. The resulting ex-
pression plasmid was separately introduced into human 
embryonic kidney (HEK) 293T cells using Lipofectamin
Ⓡ 
2000 (Invitrogen) according to the manufacturer’s instructions. 
After the transfected cells were cultured in protein-free me-
dium CD293 (Gibco/BRL), the culture supernatants were 
subjected to affinity chromatography on CNBr-Sepharose 
4B FF resin (Amersham Pharmacia Biotech) conjugated 
with anti-preS1 mAb KR127 (Maeng et al., 2000; Ryu et al., 
2000) or Protein A-agarose column (Upstate Biotechnology). 
The purified protein was quantified using NANO-DROP 
2000 (Thermo).
Indirect ELISA
Microtiter wells were coated with the purified hL1-ECD-S1 
(100 ng) diluted in 50 mM sodium carbonate buffer (pH 
9.6) at 4°C overnight and blocked with skim milk (2%) in 
PBS. The plates were washed four times with PBST (PBS 
containing 0.05% Tween 20) between steps. A10-A3 or 
cA10-A3 (0-100 ng) was added to each well, then anti- 
mouse IgG-HRP or anti-human Fc-HRP (Thermo, 1:10,000 
v/v) was added to the wells. All incubations were carried 
out at 37°C for 1 h. Color was developed with OptEIA TMB 
Substrate (BD), and the absorbance was measured at 450 
nm in a microtiter plate reader (Versa max, Molecular 
Devices).
Competition ELISA
A solution containing 3.165 ng of purified A10-A3 or 
cA10-A3 and various concentrations (5 ×10
-13-5×10
-8 
M) of the purified hL1-ECD-S1 protein was preincubated at 
37
oC for 3 h, then the mixture was added to each well coat-
ed with 100 ng of hL1-ECD-S1 and subjected to an indirect 
ELISA. Equilibrium dissociation constant (KD) was calcu-
lated from a Klotz plot (Friguet et al., 1985).
Flow cytometry
Cells were incubated with A10-A3 for 60 min at 4
oC. After 
washing twice with PBA, the cells were incubated with fluo-
rescein isothiocyanate (FITC)-conjugated anti-mouse im-
munoglobulin (Ig) (BD Pharmingen) for 30 min at 4
oC. 
Propidium iodide (PI)-negative cells were analyzed for anti-
body binding using FACSCalibur (BD Immunocytometry 
System) and Cell Quest software (BD Immunocytometry 
System). 
Cell internalization assay
SCK-L1 cells (1.5 ×10
4) were seeded in each well of cov-
er glass bottom dishes (SPL, Korea) with growth medium 
(0.1 mL) and incubated at 37ºC for 24 h. The cells were in-
cubated with A10-A3 (20 μg/ml) at 37ºC for 1 h, 3 h, 6 h 
and 12 h, washed twice with PBS, fixed with 2% paraf-
ormaldehyde, and permeabilized in PBS containing 0.2% 
Triton X-100 for 30 min on ice. The cells were blocked in 
PBS containing 2% BSA and 1% horse serum for 1 h at 
room temperature, and incubated with an Alexa-488-con-
jugated goat anti-mouse IgG (1:500) for 1 h at room tem-
perature with gentle shaking. The cells were washed 6 
times and stained with 4,6-diamidino-2-phenylindole (DAPI, 
0.25 μg/ml) in PBS containing 0.1% Triton X-100 for 20 min 
at room temperature with gentle shaking. Fluorescence im-
ages were visualized on LSM 510 META laser scanning 
confocal imaging system (Carl Zeiss, Germany). Alexa 
488-labeled A10-A3 was excited at 488 nm, and emission 
was recorded at 505-550 nm. DAPI was excited at 405 nm, 
and emission was recorded at 420-480 nm.
L1CAM homophilic binding assay
Microtiter plates were coated with anti-human IgG (Fc spe-
cific; Pierce) at a concentration of 25 μg/mL for 1 h at 
37°C, then purified hL1-ECD-Fc or Ig1-Fc was added to 
each well at 2 μM concentration and incubated at 37°C for 
2 h. Control wells were coated with 2 μM BSA. After wash-
ing with PBST, hL1-ECD-S1 (2 μM in PBS containing 1% 
BSA) was added to each well and incubated at 37°C for 3 
h. To examine whether A10-A3 inhibits L1CAM homophilic 
binding, the hL1-ECD-S1 was preincubated with A10-A3 
(0-50 μg) at 37°C for 3 h, then the mixture was added to 
each well containing hL1-ECD-Fc and incubated at 37°C 
for 3 h. To detect the bound hL1-ECD-S1, KR127 was con-
jugated with HRP using EZ-Link
Ⓡ Plus Activated 
Peroxidase (Thermo), and the resulting KR127-HRP con-
jugate (1:1,000 v/v) was added to each well and incubated 
at 37°C for 1 h. Color was developed with OptEIA TMB 
Substrate, and the absorbance was measured at 450 nm 
in a microtiter plate reader. Data are shown as means of 
triplicates ± SD. 
Cell adhesion assay
SCK-L1 cells (2 ×10
4) in DMEM were preincubated with 
10 μg /ml of A10-A3, UJ127 (Abcam), or KR127 at 37°C 
for 3 h and incubated with hL1-ECD-Fc, Ig5-6/Fn1-5-Fc, or 
Ig1-Fc that had been captured by anti-human IgG at 37°C 
for 3 h. After washing with PBS three times, the attached 
cells were measured using a WST1 assay kit (Roche). 
Absorbance was measured at 450 nm in a microtiter plate 
reader. Data are shown as means of triplicates ± SD. 
Cell proliferation assay 
Cells (2 ×10
5) were seeded in 6-well dishes (Falcon, 
Milian SA, Geneva, Switzerland) in 3 ml medium contain-
ing 10% FBS. After 12 h, when cells had attached to the 
plates, antibody (10 μg/ml) or PBS was added. After 72 h, 
cells were detached in PBS containing 1 mM EDTA, wash-
ed twice in PBS, and counted in a hemocytometer.300    Exp. Mol. Med. Vol. 44(4), 293-302, 2012
Construction and production of chimeric antibody 
For the cloning of the cDNAs encoding the heavy chain 
variable region (VH) or light chain variable region (VL) of 
A10-A3 (IgG1, κ), total RNAs were isolated from A10-A3 
hybridoma (Min et al., 2010) and the cDNAs encoding the 
variable regions were synthesized by polymerase chain re-
action (PCR) using the 5'-primers specific for the VH or VL 
of murine antibodies (Kim et al., 2008) and the 3'-primers 
specific for the mouse Cγ1 or Cκ. After the cDNA syn-
thesis, the PCR products were subcloned into pBluescript 
SK (+). The three clones of the VH or VL cDNA were 
sequenced. To determine the N-terminal sequences of the 
heavy and light chains of A10-A3, each chain was isolated 
after SDS-PAGE and subjected to N-terminal sequencing. 
For the expression of cA10-A3, the cDNAs encoding the 
VH or VL with cognate leader sequence were fused to hu-
man Cγ1 or Cκ by subcloning into the EcoRI-ApaI or 
HindIII-BsiWI site, respectively, of pdCMV-dhfrC derived 
from pdCMV-dhfr-AKA (Yoon et al., 2006). The resulting 
expression plasmid, pdCMV-dhfrC-cA10A3 was introduced 
into DG44 cells using Lipofectamine
Ⓡ 2000 (Invitrogen) ac-
cording to the manufacturer’s protocol. Stably transfected 
cell lines were selected in a medium containing G418 (550 
μg/ml) and subsequently subjected to MTX selection for 
gene amplification, as described previously (Yoon et al., 
2006). A recombinant CHO cell line secreting the chimeric 
antibody was grown in serum-free medium (CHO-S-SFMII, 
GIBCO/BRL), and the culture supernatant was subjected 
to affinity chromatography on Protein A-Sepharose 4B col-
umn (GE Lifesciences) according to the supplier’s instruction. 
The purity and integrity of the purified antibody were as-
sessed by 2100 Bioanalyzer (Agilent Technologies). For 
the quantification of the purified antibody, the optical den-
sity of 1.43 at 280 nm was taken for the protein concen-
tration of 1 mg/ml. 
Antibody-dependent cell-mediated cytotoxicity 
(ADCC) assay
PBMC as effector cells were isolated from blood of three 
healthy donors by density gradient centrifugation using 
Histopaque (Sigma-Aldrich). SCK-L1 as target cells (5 ×
10
3) were plated into each well of a 96-well plate contain-
ing phenol red free RPMI-1640 medium (50 μl) with 1% 
FBS. Then, serially diluted antibody solution (25 μl) was 
added to the target cells and incubated for 15 min in 5% 
CO2, 37
oC humidified incubator. After 15 min, the target 
cells were incubated with the ratio of E:T 30:1 or 60:1 of 
freshly prepared PBMC (25 μl) for 4 h. The cytotoxicity was 
determined by measuring the LDH activity released from 
the cytosol of damaged cells using Cytotoxicity Detection 
Kit PLUS (LDH) (Roche Applied Science, Germany). 
Spontaneous release was determined by incubating target 
cells with antibody in RPMI medium containing 1% FBS, 
and maximum release was determined by complete lysis of 
target cells in RPMI-1640 medium containing 1% FBS with 
the cell lysis solution provided in the kit. Nonspecific re-
lease was determined by incubating target cells with 
PBMC in RPMI medium containing 1% FBS. The percent-
age of specific lysis was calculated as [specific lysis (%) = 
(specific release-nonspecific release) / (maximum release- 
spontaneous release) ×100], as described previously 
(Horton et al., 2008). Data are expressed as the mean of 
triplicate wells.
Xenograft nude mice assay 
Nude mice (BALB/c Slc-nu, 5 weeks old) were obtained 
from Japan SLC, Inc (Japan). Mice were housed under 
specific pathogen free conditions for 7 days in accordance 
with the guidelines of the Animal Care Committee at 
Biotoxtech Co., Ltd (Ochang, Korea). Choi-Ck tumor tissue 
(8 mm
3) was inoculated s.c. into the back of each mouse. 
After 7 days, when tumor volume reached 65-93 mm
3 (n=
10 per group), cA10-A3 or Synagis as an isotype control at 
a dose of 10 mg/kg was injected intravenously three times 
per week for 28 days. Tumor growth was monitored bi-
weekly by measuring the length and width of the tumor 
with a caliper and calculating tumor volume on the basis of 
the following formula: volume=0.523Lw
2, where L is 
length and W is width. On day 40, mice were euthanized. 
To determine the toxicity to the animals, the body weight of 
the animals was measured twice a week.
Statistical analysis 
Data are presented as mean ± SD. and statistical compar-
isons between groups were performed using one-way 
ANOVA followed by Student's t test. A value of P ＜0.05 
was considered significant. 
Supplemental data
Supplemental data include a figure and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-44-4-05.pdf.
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